Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01774968 · ClinicalTrials.gov registry record · Phase 4

Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

A Phase 4 study, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 4
Development phase
325
Enrollment target

NCT01774968 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 325 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01774968, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 4
Development phase
325 participants
Enrollment target

Study Summary

The main purpose of this study is to compare the effectiveness of Human Regular U-500 Insulin three times a day versus twice a day.

Interventions

  • DRUG Human Regular U-500 Insulin

Trial Details

FieldValue
Enrollment Target 325 participants
Start Date 2013-02
Est. Completion 2014-05
Phase Phase 4

Sponsor

Eli Lilly and Company

1,341 total trials

What the Registry Record Tells You About NCT01774968

The ClinicalTrials.gov registry entry for NCT01774968 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 325 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Human Regular U-500 Insulin is the first listed.

NCT01774968 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01774968 about?

NCT01774968 is a clinical study titled "Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes". The main purpose of this study is to compare the effectiveness of Human Regular U-500 Insulin three times a day versus twice a day.

What is the current status of trial NCT01774968?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 325 participants. The study started on 2013-02. Estimated completion is 2014-05.

What interventions are being tested in trial NCT01774968?

The interventions under investigation include: Human Regular U-500 Insulin (DRUG).

Who is sponsoring clinical trial NCT01774968?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.